FTAI is up +138.36% since Oct ’23 pick Unlock All Top Buy Picks
$0.701
-0.0162 (-2.26%)
At Close: May 31, 2024
Forecast Earnings Fundamentals Insider Trading Signals Historical Prices Predictions Profile

Information

1901 West 47th Place

Kansas City KS 66205

913 942 2300

www.cingulate.com

Industry: Biotechnology

Sector: Healthcare

Cingulate Inc.

Description

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Click to get the best stock tips daily for free!

About Cingulate Inc.

Cingulate. Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety diso... CING Profile

Golden Star

Ticker Date Change Price
OXM May 29 3.64% $106.80
UTZ May 29 2.43% $18.10
DVAX May 29 3.99% $11.53
GNTX May 28 1.66% $34.43
OHI May 20 4.76% $30.86
CNI May 16 0.600% $126.57
TTWO May 16 9.78% $146.08
RL May 15 11.92% $166.98
LNG May 14 0.235% $157.42
VCLT May 14 0.277% $75.73
Unlock

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT